We have investigated the effect of the v-Myc oncoprotein on gene expression in myelomonocytic cells. We find that v-Myc dramatically down-regulates the expression of myelomonocytic-specific genes, such as the chicken mim-1 and lysozyme genes, both of which are known targets for C/EBP transcription factors. We present evidence that Myc downregulates these genes by inhibiting the function of C/EBP transcription factors. Detailed examination of the inhibitory mechanism shows that amino-terminal sequences of v-Myc, but not its DNA-binding domain, are required for the suppression of C/EBP-dependent transactivation. Our findings identify a new function for Myc and reveal a novel mechanism by which Myc affects the expression of other genes.
Numerous studies have implicated the c-myc gene in a variety of cellular processes, such as proliferation, differentiation, and apoptosis, and have shown that mutant forms of the gene, such as transduced (v-myc) or rearranged myc alleles, are involved in tumorigenesis (1) (2) (3) (4) (5) (6) . It is now widely believed that c-myc plays a central role in a switch mechanism by which normal cells decide between the alternative fates of proliferation, differentiation, and apoptosis and that deregulation of c-myc causes an imbalance in this switch mechanism, resulting in the development of neoplasia.
Structural and functional analyses have identified the c-myc protein product (c-Myc) as a transcription factor. The carboxyl terminus of c-Myc forms a basic region-helix-loop-helixleucine zipper (B-HLH-LZ) DNA-binding domain, heterodimerizes with the Max protein (7) , and recognizes the consensus Myc binding site, CACGTG (8) (9) (10) , whereas the amino terminus of c-Myc functions as a transcriptional activation domain (11) (12) (13) (14) . Several genes whose expression is induced by c-Myc have been identified (15) (16) (17) (18) (19) (20) . In addition, c-Myc also inhibits gene expression. The C/EBPa gene (21, 22) and the adenovirus-2 major late promoter (22, 23) are downregulated by c-Myc. Interestingly, repression of these genes does not depend on Myc-specific DNA-binding sites but is mediated by so-called initiator elements located in the promoters of these genes (22, 23) . Thus, increasing evidence suggests that c-Myc affects gene expression by several different mechanisms. Nevertheless, an unambiguous functional relationship to the physiological or malignant activities of myc has not been established for any of the putative target genes identified so far.
We have studied the effect of v-Myc on gene expression in myelomonocytic cells. We have found that v-Myc inhibits the expression of several genes, including mim-1 and the lysozyme gene, both of which have been shown to be targets for C/EBP transcription factors (24, 25) . We have analyzed the mechanism by which Myc down-regulates these genes and have found that amino-terminal sequences of Myc interfere with the function of C/EBP transcription factors. Our findings identify a novel function for Myc and reveal a novel mechanism by which Myc affects the expression of other genes.
MATERIALS AND METHODS
Cells. BM2 is a line of avian myeloblastosis virustransformed chicken myeloblasts (26) . Infection of BM2 cells with MC29 virus has been described (27) (30) and encodes the MC29-specific Gag-Myc fusion protein. pMC29(Q10-4)Notfs is a derivative of pMC29(Q10-4) carrying a frameshift at a unique NotI restriction site in the v-myc-coding region. pSPc-myc (14) encodes human c-Myc. pRCAS-wtMyc encodes v-Myc initiated at the authentic Myc start codon and lacking gag-derived amino acid sequences. pRCAS-MycH336G is a point-mutated derivative of pRCASwtMyc with a His-336 -* Ala substitution (S. Scheidler, R.W., M. Hartl, and K.B., unpublished data). pCDNA3-wtMyc encodes v-Myc initiated at the authentic Myc start codon and was constructed by cloning the v-myc-specific sequences of MC29 into pCDNA3 (Invitrogen). pCDNA3-B2Myc, pCDNA3-HlMyc, pCDNA3-H2Myc, pCDNA3-APAMyc and pCMVMycAVP16 are derivatiVes of pCDNA3-wtMyc. In mutant Myc proteins B2, Hi, and H2, specific amino acid residues were substituted using site-directed mutagenesis (31 (32) and was obtained from P. Chambon (CNRS, Strasbourg, France). pRSVc-jun encodes human c-Jun; the pRSVc-jun stop is a frameshift derivative of pRSVc-jun (33) .
Transfections and Northern Blotting. The reporter plasmids p3xTRECAT (33), p-240Luc (34), pC3Luc200 (35) , pluclOOO (36) , and pCH110 (Pharmacia) have been described. pG5E4-38Luc contains five Gal4-binding sites upstream of the adenovirus E4 promoter (positions -38 to +38) and the luciferase gene. QT6 cells were transfected as described (24) . The amounts of DNA used are indicated in the figure legends and refer to a 10-cm cell culture dish. Luciferase, chloramphenicol acetyltransferase, and 13-galactosidase assays were performed 48 hr after transfection as described (24) . Detection of the chicken mim-1, lysozyme, chicken C/EBPa and C/EBPI3, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs by Northern blotting has been described (24) .
RESULTS
Inhibition of mim-1 and Lysozyme Gene Expression by v-Myc. To identify target genes for v-Myc in myelomonocytic cells, we searched for genes differentially expressed between the avian myeloblastosis virus-transformed chicken myeloblast cell line BM2 (26) and subclones of this line infected with the chicken retrovirus MC29 (27) . To our surprise, by simply comparing the expression of known genes in these cells, we identified several genes whose expression was down-regulated by v-Myc. As shown in (24, 25) , raising the possibility that the v-Myc-induced downregulation is mediated by C/EBP. Consistent with this idea, our finding was that the levels of C/EBPa and C/EBP,3 mRNA were suppressed in BM2 cells expressing v-Myc (Fig. 1C) .
To determine whether v-Myc exerts its effect only on the level of C/EBP expression, we cotransfected a mim-1 reporter gene with a constitutively active C/EBPP3 expression vector, either in the presence or in the absence of v-Myc. Interestingly, the ability of C/EBPf3 to activate the mim-1 promoter was strongly compromised in the presence of v-Myc ( Fig. 2A) To examine the specificity of the inhibitory effect, we asked if v-Myc also inhibits other transcription factors. Transactivation by chicken C/EBPa was strongly suppressed by v-Myc (Fig. 2C) . We confirmed by Western blotting that the amount of C/EBPa was not reduced in the presence of v-Myc (data not shown). Thus, the inhibitory effect of v-Myc affects several C/EBP family members. By contrast, transactivation by c-Jun or a Gal4-VP16 hybrid protein was not inhibited by v-Myc (Fig. 2C) (Fig. 3A) . In the Myc mutant His-336 -> Gly, a histidine in the basic region of v-Myc, which is involved in the specific amino acid-base contacts in the Myc-DNA complex (38) (Fig. 3A and  B) . To substantiate this conclusion, additional mutations were generated in the basic region (B2) and the HLH region (Hi, H2) of v-Myc, all of which had completely lost DNA-binding activity (31) . As illustrated in Fig. 3C , all of the mutants inhibited C/EBP/ and C/EBPa (data not shown) with an activity similar to the unmutated v-Myc, suggesting that the DNA-binding function of v-Myc is not required for the inhibition of C/EBP. By contrast, an amino-terminal deletion mutant of v-Myc (APA) was unable to inhibit C/EBPI3 (Fig.  3C ), although this protein was expressed at a level similar to the wild-type protein (data not shown). Thus, the experiments shown in Fig. 3 suggested that the inhibition of C/EBP depends on the amino terminus of v-Myc, but not on its DNA-binding domain. Furthermore, the expression of the fusion proteins can conveniently be monitored using Gal4-specific antibodies. In agreement with the results obtained with the v-Myc mutants containing specific amino acid substitutions in the B-HLH domain, several of the Gal4-v-Myc fusion proteins, which completely lack the Myc DNA-binding domain, were fully active in inhibiting C/EBPP3 (Fig. 4) . By contrast, mutants having a deletion endpoint close to the highly conserved Myc-box 1 or lacking Myc-box 1 however, lead to a loss of the inhibitory activity of Myc (Fig.  4) . This result suggested that the carboxyl-terminal half of Myc box 1 or sequences located between Myc boxes 1 and 2 are responsible for the inhibition.
DISCUSSION
It is widely believed that c-Myc controls a switch by which cells select between the alternative fates of proliferation, differentiation, and apoptosis. Attempts to identify target genes for Myc involved in this switch have focused so far almost exclusively on fibroblasts and on genes involved in transformation. To identify genes whose expression is affected by Myc in differentiating cells, we have studied the effect of v-Myc on a myelomonocytic chicken cell line. We have identified several genes whose expression is repressed by v-Myc in these cells. Analysis of repression of the these genes by Myc has revealed a novel function of Myc: inhibition of C/EBP-mediated gene expression. This novel inhibitory activity appears to be due to the ability of Myc to interfere with the function of C/EBP transcription factors.
It is important to distinguish between inhibition of C/EBP function and suppression of C/EBP expression. Myc inhibits C/EBPa-and C/EBP,B-mediated transactivation even when the amounts of these transcription factors remain constant. Thus, the inhibitory activity of Myc is exerted on the level of C/EBP protein function. However, Myc also down-regulates C/EBPa and C/EBP,B gene expression. The promoters of these genes contain C/EBP binding sites and are up-regulated by their own gene products (22, 39; unpublished (40) . The inhibition of C/EBP cannot be explained by competition of v-Myc and C/EBP for the same binding sites, because the inhibitory effect does not require the DNA-binding function of Myc. This also excludes as a possible mechanism binding to and activation by Myc of other genes whose products then interfere with C/EBP. That the amino terminus of Myc is required for inhibition of C/EBP is somewhat reminiscent of the repression of the adenovirus-2 major late promoter and of C/EBPa genes, which also involves the amino-terminal domain of Myc (22) . In these cases, however, the inhibition is mediated by initiator elements present in the promoters of the repressed genes. The inhibitory mechanism described here is distinct from this initiator-dependent repression mechanism, because the mim-1 and lysozyme gene promoters lack initiator elements. Furthermore, Myc box 2 is required for the initiatordependent inhibition mechanism (22) but is dispensable for the inhibition of C/EBP-dependent transactivation. We note that the C/EBPa promoter, which contains C/EBP binding sites as well as an initiator element, can be inhibited by Myc by two different mechanisms. This suggests a complex relationship between Myc and C/EBPa expression.
What is the biological relevance of the suppression of C/EBP-dependent transactivation by Myc? A number of studies suggest important roles for C/EBP in differentiation processes. Several C/EBP isoforms are directly involved in the transcription of differentiation-specific genes in terminally differentiated liver cells, fat cells, and macrophages (24, 25, (41) (42) (43) (44) (45) (46) . High levels of C/EBP expression inhibit cell proliferation and, thus, appear to be responsible for the proliferation arrest of terminally differentiated cells (21, 47, 48) . Finally, antisense inhibition of C/EBPa mRNA is sufficient to block fat cell differentiation (45) . Several studies have shown that Myc inhibits myelomonocytic as well as fat cell differentiation (24, 27, 49) . Given the relevance of C/EBP proteins for these differentiation processes, our findings raise the intriguing possibility that the suppression of C/EBP is causally related to the inhibition of C/EBP-dependent differentiation processes by Myc. Whether the novel function of Myc described here also plays a role in oncogenic transformation is unclear. Numerous studies have shown that cell trahsformation by Myc depends on its DNA-binding function, suggesting that transformation involves the direct activation or suppression of certain as yet unknown target genes by Myc. However, it is possible that inhibition of C/EBP, whose expression at high levels leads to growth arrest, provides an additional mechanism for locking transformed cells in a proliferative state. Further work is required to explore these ideas and to understand, on the molecular level, how Myc suppresses C/EBP-mediated gene activation. Since cross-talk between different transcription factors often involves direct proteinprotein contacts, it wiMl be interesting to determine whether the inhibitory mechanism described here is facilitated by direct protein-protein interactions involving Myc and C/EBP. In any case, the increasing complexity and surprising diversity of mechanisms by which Myc affects the expression of other genes underlines its role as a multifunctional integration point in the transcription factor network.
